News & Updates

Show Multimedia Only

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024 by

In the prespecified interim analysis of the phase III ALIGN study, the investigational drug atrasentan shows promising signals when added to standard supportive care with a renin-angiotensin system (RAS) inhibitor in patients with IgA nephropathy (IgAN).

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024

Precise utilisation of triple therapy inhalers can reduce the burden of asthma in Singapore

07 Jun 2024

On 16 April 2024, GSK organised the Trelegy Asthma: Release From Constriction seminar in Singapore. The event featured talks from distinguished experts, Associate Professor Loo Chian Min and Professor Simon Bowler who provided insights on the disease burden of asthma in Singapore and how a precision medicine approach with the single-inhaler triple therapy, Trelegy Ellipta, can improve lung function and symptom control in patients with uncontrolled asthma. The session was chaired by Dr Kenneth Chan.

Precise utilisation of triple therapy inhalers can reduce the burden of asthma in Singapore

07 Jun 2024

Increased practice of Chinese calligraphy strengthens brain network in older adults

07 Jun 2024 by

Increased practice of Chinese calligraphy strengthens brain network in older individuals who already practice the cognitive activity regularly and experienced subjective cognitive decline (SCD), a two-arm, parallel-design, assessor-blind, randomized controlled trial conducted by the Chinese University of Hong Kong (CUHK) has found.

Increased practice of Chinese calligraphy strengthens brain network in older adults

07 Jun 2024

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

Glucose-lowering drugs such as the glucagon-like peptide-1 receptor agonist (GLP-1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and dipeptidyl peptidase-4 inhibitor (DPP-4i) work better and are more cost-effective than sulfonylureas and glinides (SU) as second-line treatment for type 2 diabetes (T2D), according to a population-based retrospective cohort study.

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

Faster ageing blamed for global surge in early-onset cancers

06 Jun 2024 by

People born in 1965 or later show signs of accelerated ageing, a phenomenon that is potentially related to the rising incidence of early-onset solid tumours worldwide, according to a large study.

Faster ageing blamed for global surge in early-onset cancers

06 Jun 2024

Does metoclopramide improve endoscopic visualization in patients with UGIB?

06 Jun 2024

Use of metoclopramide proves inadequate in enhancing endoscopic visualization among patients with overall active upper gastrointestinal bleeding (UGIB), reports a study. However, it does reduce the need for second look esophagogastroduodenoscopy (EGD).

Does metoclopramide improve endoscopic visualization in patients with UGIB?

06 Jun 2024

Can prophylactic biologic mesh in IC prevent parastomal hernia?

06 Jun 2024 by

Use of biologic mesh at the time of ileal conduit (IC) construction is safe and feasible in patients undergoing cystectomy but falls short of providing protective effects against parastomal hernia (PSH) within 2 years following surgery, reports a study.

Can prophylactic biologic mesh in IC prevent parastomal hernia?

06 Jun 2024

Low-carb diet eases pain, improves QoL in women with lipedema

06 Jun 2024

Women with lipedema who lose weight through proper diet can see improvements in their quality of life (QoL), suggests a study. Specifically, an energy-restricted low-carbohydrate diet (LCD) appears to be better at pain reduction than a standard control diet.

Low-carb diet eases pain, improves QoL in women with lipedema

06 Jun 2024

COVID-19 does mess with the brain even years after infection

06 Jun 2024 by

A long-term study showed that individuals who have recovered from COVID-19 continued to experience cognitive, psychiatric, and neurological issues, as well as brain functional alteration, even 2 years after being infected.

COVID-19 does mess with the brain even years after infection

06 Jun 2024

CD38 monoclonal antibody shows promise in kidney transplant rejection

06 Jun 2024

In the treatment of kidney transplant recipients with antibody-mediated rejection, the CD38 monoclonal antibody felzartamab demonstrates acceptable safety and side-effect profiles as well as potential therapeutic benefit, according to a phase II trial.

CD38 monoclonal antibody shows promise in kidney transplant rejection

06 Jun 2024

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Atrasentan a new player in the IgAN treatment field?

Atrasentan a new player in the IgAN treatment field?

Precise utilisation of triple therapy inhalers can reduce the burden of asthma in Singapore

Precise utilisation of triple therapy inhalers can reduce the burden of asthma in Singapore

Increased practice of Chinese calligraphy strengthens brain network in older adults

Increased practice of Chinese calligraphy strengthens brain network in older adults

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

Faster ageing blamed for global surge in early-onset cancers

Faster ageing blamed for global surge in early-onset cancers

Does metoclopramide improve endoscopic visualization in patients with UGIB?

Does metoclopramide improve endoscopic visualization in patients with UGIB?

Can prophylactic biologic mesh in IC prevent parastomal hernia?

Can prophylactic biologic mesh in IC prevent parastomal hernia?

Low-carb diet eases pain, improves QoL in women with lipedema

Low-carb diet eases pain, improves QoL in women with lipedema

COVID-19 does mess with the brain even years after infection

COVID-19 does mess with the brain even years after infection

CD38 monoclonal antibody shows promise in kidney transplant rejection

CD38 monoclonal antibody shows promise in kidney transplant rejection